Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Conivaptan is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Conivaptan is combined with Levodopa. |
| Risperidone | Conivaptan may increase the hypotensive activities of Risperidone. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Conivaptan. |
| Armodafinil | The metabolism of Conivaptan can be increased when combined with Armodafinil. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Conivaptan. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Conivaptan. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Conivaptan. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Conivaptan. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Conivaptan. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Conivaptan. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Conivaptan. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Conivaptan. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Conivaptan. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Conivaptan. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Conivaptan. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Conivaptan. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Conivaptan. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Conivaptan. |
| Fentanyl | The metabolism of Fentanyl can be decreased when combined with Conivaptan. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Conivaptan. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Conivaptan. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Conivaptan. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Conivaptan. |
| Metreleptin | The metabolism of Conivaptan can be increased when combined with Metreleptin. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Conivaptan. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Conivaptan. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Conivaptan. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Conivaptan. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan. |
| Crizotinib | The metabolism of Conivaptan can be decreased when combined with Crizotinib. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Conivaptan. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Conivaptan. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Conivaptan. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Conivaptan. |
| Linezolid | Linezolid may increase the orthostatic hypotensive activities of Conivaptan. |
| Furazolidone | Furazolidone may increase the orthostatic hypotensive activities of Conivaptan. |
| Procaine | Procaine may increase the orthostatic hypotensive activities of Conivaptan. |
| Minaprine | Minaprine may increase the orthostatic hypotensive activities of Conivaptan. |
| Procarbazine | Procarbazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Moclobemide | Moclobemide may increase the orthostatic hypotensive activities of Conivaptan. |
| Isocarboxazid | Isocarboxazid may increase the orthostatic hypotensive activities of Conivaptan. |
| Rasagiline | Rasagiline may increase the orthostatic hypotensive activities of Conivaptan. |
| Pargyline | Pargyline may increase the orthostatic hypotensive activities of Conivaptan. |
| Clorgiline | Clorgiline may increase the orthostatic hypotensive activities of Conivaptan. |
| Iproniazid | Iproniazid may increase the orthostatic hypotensive activities of Conivaptan. |
| Nialamide | Nialamide may increase the orthostatic hypotensive activities of Conivaptan. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Conivaptan. |
| Hydracarbazine | Hydracarbazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Pirlindole | Pirlindole may increase the orthostatic hypotensive activities of Conivaptan. |
| Toloxatone | Toloxatone may increase the orthostatic hypotensive activities of Conivaptan. |
| Benmoxin | Benmoxin may increase the orthostatic hypotensive activities of Conivaptan. |
| Mebanazine | Mebanazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Octamoxin | Octamoxin may increase the orthostatic hypotensive activities of Conivaptan. |
| Pheniprazine | Pheniprazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Phenoxypropazine | Phenoxypropazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Pivhydrazine | Pivhydrazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Safrazine | Safrazine may increase the orthostatic hypotensive activities of Conivaptan. |
| Caroxazone | Caroxazone may increase the orthostatic hypotensive activities of Conivaptan. |
| Harmaline | Harmaline may increase the orthostatic hypotensive activities of Conivaptan. |
| Brofaromine | Brofaromine may increase the orthostatic hypotensive activities of Conivaptan. |
| Tranylcypromine | Tranylcypromine may increase the orthostatic hypotensive activities of Conivaptan. |
| Hexobarbital | Hexobarbital may increase the hypotensive activities of Conivaptan. |
| Methohexital | Methohexital may increase the hypotensive activities of Conivaptan. |
| Thiopental | Thiopental may increase the hypotensive activities of Conivaptan. |
| Streptokinase | The risk or severity of adverse effects can be increased when Streptokinase is combined with Conivaptan. |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Conivaptan. |
| Ropinirole | The risk or severity of adverse effects can be increased when Ropinirole is combined with Conivaptan. |
| Triamterene | The risk or severity of adverse effects can be increased when Triamterene is combined with Conivaptan. |
| Spironolactone | The risk or severity of adverse effects can be increased when Spironolactone is combined with Conivaptan. |
| Nabilone | The metabolism of Nabilone can be decreased when combined with Conivaptan. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Conivaptan. |
| Amiloride | The risk or severity of adverse effects can be increased when Amiloride is combined with Conivaptan. |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Conivaptan. |
| Tizanidine | The risk or severity of adverse effects can be increased when Tizanidine is combined with Conivaptan. |
| Apomorphine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan. |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Conivaptan. |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Conivaptan is combined with Etacrynic acid. |
| Levosimendan | The risk or severity of adverse effects can be increased when Conivaptan is combined with Levosimendan. |
| Thalidomide | The metabolism of Thalidomide can be decreased when combined with Conivaptan. |
| Iloprost | The risk or severity of adverse effects can be increased when Conivaptan is combined with Iloprost. |
| Papaverine | The risk or severity of adverse effects can be increased when Conivaptan is combined with Papaverine. |
| Amifostine | The risk or severity of adverse effects can be increased when Conivaptan is combined with Amifostine. |
| Diclofenamide | The risk or severity of adverse effects can be increased when Conivaptan is combined with Diclofenamide. |
| Desflurane | The risk or severity of adverse effects can be increased when Conivaptan is combined with Desflurane. |
| Carbetocin | The risk or severity of adverse effects can be increased when Conivaptan is combined with Carbetocin. |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Conivaptan is combined with Amyl Nitrite. |
| Nesiritide | The risk or severity of adverse effects can be increased when Conivaptan is combined with Nesiritide. |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Conivaptan is combined with Azilsartan medoxomil. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Conivaptan is combined with Obinutuzumab. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Conivaptan is combined with Isoxsuprine. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Conivaptan is combined with Dinutuximab. |
| Nitrous acid | The risk or severity of adverse effects can be increased when Conivaptan is combined with Nitrous acid. |
| Fimasartan | The risk or severity of adverse effects can be increased when Conivaptan is combined with Fimasartan. |
| Pipamperone | The risk or severity of adverse effects can be increased when Conivaptan is combined with Pipamperone. |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Conivaptan. |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Conivaptan. |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Conivaptan. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Conivaptan. |